Abstract
Despite recent advances in oncologic therapy, an important proportion of patients with primary cancer will develop distant metastasis. The standard therapy for metastatic cancer is systemic therapy, which typically does not yield excellent response rates for most solid tumors. Data in the literature support the existence of a state of limited metastasis or oligometastasis. Favorable outcomes have been observed in selected patients with oligometastases that are treated with local ablative therapies, which include surgical extirpation, stereotactic body radiation therapy, and radiofrequency ablation. Lung and liver are the two most common sites of oligometastases considered for local ablative therapy and this Review will focus on the role of local therapy in oligometastases that arise in these organs.
Key Points
-
Data in the literature suggest the existence of oligometastasis, a state in which metastases are limited in site and number
-
Different types of local therapies have been used for the treatment of limited metastases, mostly in the lung and liver
-
A large body of data in the literature on metastatectomy in patients with lung and liver oligometastases show that survival can be increased in some patients
-
Data on the use of stereotactic body radiation therapy and radiofrequency ablation are emerging and the early results on local control are promising
-
The biggest challenge is to identify those patients who will benefit from the treatment of their oligometastatic disease with local aggressive therapy
-
The selection of local therapy should involve interdisciplinary discussion among surgeons, radiation oncologists, and medical oncologists, as well as patients
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Hellman, S. & Weichselbaum, R. R. Oligometastases revisited. Nat. Rev. Clin. Oncol. doi: 10.1038/nrclinonc.2011.44.
Lo, S. S. et al. Stereotactic body radiation therapy for oligometastases. Expert Rev. Anticancer Ther. 9, 621–635 (2009).
[No authors listed] Long-term results of lung metastasectomy: prognostic analyses based on 5206 cases. The International Registry of Lung Metastases. J. Thorac. Cardiovasc. Surg. 113, 37–49 (1997).
Onaitis, M. W. et al. Prognostic factors for recurrence after pulmonary resection of colorectal cancer metastases. Ann. Thorac. Surg. 87, 1684–1688 (2009).
Petersen, R. P. et al. Improved survival with pulmonary metastasectomy: an analysis of 1720 patients with pulmonary metastatic melanoma. J. Thorac. Cardiovasc. Surg. 133, 104–110 (2007).
Fong, Y. et al. Liver resection for colorectal metastases. J. Clin. Oncol. 15, 938–946 (1997).
Fong, Y., Fortner, J., Sun, R. L., Brennan, M. F. & Blumgart, L. H. Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases. Ann. Surg. 230, 309–318 (1999).
Choti, M. A. et al. Trends in long-term survival following liver resection for hepatic colorectal metastases. Ann. Surg. 235, 759–766 (2002).
Kopetz, S. et al. Improved survival in metastatic colorectal cancer is associated with adoption of hepatic resection and improved chemotherapy. J. Clin. Oncol. 27, 3677–3683 (2009).
Pawlik, T. M. et al. Effect of surgical margin status on survival and site of recurrence after hepatic resection for colorectal metastases. Ann. Surg. 241, 715–722 (2005).
Fernandez, F. G. et al. Five-year survival after resection of hepatic metastases from colorectal cancer in patients screened by positron emission tomography with F-18 fluorodeoxyglucose (FDG-PET). Ann. Surg. 240, 438–447 (2004).
Timmerman, R. D. et al. Local surgical, ablative, and radiation treatment of metastases. CA Cancer J. Clin. 59, 145–170 (2009).
Lo, S. S. et al. Stereotactic body radiation therapy: a novel treatment modality. Nat. Rev. Clin. Oncol. 7, 44–54 (2010).
Rusthoven, K. E. et al. Multi-institutional phase I/II trial of stereotactic body radiation therapy for lung metastases. J. Clin. Oncol. 27, 1579–1584 (2009).
Rusthoven, K. E. et al. Multi-institutional phase I/II trial of stereotactic body radiation therapy for liver metastases. J. Clin. Oncol. 27, 1572–1578 (2009).
Lee, M. T. et al. Phase I study of individualized stereotactic body radiotherapy of liver metastases. J. Clin. Oncol. 27, 1585–1591 (2009).
Rule, W. et al. Phase I dose-escalation study of stereotactic body radiotherapy in patients with hepatic metastases. Ann. Surg. Oncol. 18, 1081–1087 (2011).
Le, Q. T. et al. Results of a phase I dose-escalation study using single-fraction stereotactic radiotherapy for lung tumors. J. Thorac. Oncol. 1, 802–809 (2006).
Okunieff, P. et al. Stereotactic body radiation therapy (SBRT) for lung metastases. Acta Oncol. 45, 808–817 (2006).
Katz, A. W. et al. Hypofractionated stereotactic body radiation therapy (SBRT) for limited hepatic metastases. Int. J. Radiat. Oncol. Biol. Phys. 67, 793–798 (2007).
Herfarth, K. K. et al. Stereotactic single-dose radiation therapy of liver tumors: results of a phase I/II trial. J. Clin. Oncol. 19, 164–170 (2001).
Hof, H., Hoess, A., Oetzel, D., Debus, J. & Herfarth, K. Stereotactic single-dose radiotherapy of lung metastases. Strahlenther. Onkol. 183, 673–678 (2007).
Zhu, J. C., Yan, T. D. & Morris, D. L. A systematic review of radiofrequency ablation for lung tumors. Ann. Surg. Oncol. 15, 1765–1774 (2008).
Norton, L. & Simon, R. The Norton-Simon hypothesis revisited. Cancer Treat. Rep. 70, 163–169 (1986).
Mehta, N. et al. Analysis of further disease progression in metastatic non-small cell lung cancer: implications for locoregional treatment. Int. J. Oncol. 25, 1677–1683 (2004).
Rusthoven, K. E. et al. Is there a role for consolidative stereotactic body radiation therapy following first-line systemic therapy for metastatic lung cancer? A patterns-of-failure analysis. Acta Oncol. 48, 578–583 (2009).
Kavanagh, B. D., McGarry, R. C. & Timmerman, R. D. Extracranial radiosurgery (stereotactic body radiation therapy) for oligometastases. Semin. Radiat. Oncol. 16, 77–84 (2006).
Ollila, D. W. & Caudle, A. S. Surgical management of distant metastases. Surg. Oncol. Clin. N. Am. 15, 385–398 (2006).
National Comprehensive Cancer Network NCCN Clinical Practice Guidelines in Oncology: Colon Cancer [online], (2011).
Welter, S., Jacobs, J., Krbek, T., Krebs, B. & Stamatis, G. Long-term survival after repeated resection of pulmonary metastases from colorectal cancer. Ann. Thorac. Surg. 84, 203–210 (2007).
Pfannschmidt, J., Dienemann, H. & Hoffmann, H. Surgical resection of pulmonary metastases from colorectal cancer: a systematic review of published series. Ann. Thorac. Surg. 84, 324–338 (2007).
Riquet, M. et al. Pulmonary resection for metastases of colorectal adenocarcinoma. Ann. Thorac. Surg. 89, 375–380 (2010).
National Comprehensive Cancer Network NCCN Clinical Practice Guidelines in Oncology: Soft Tissue Sarcoma [online], (2011).
Suri, R. M. et al. Pulmonary resection for metastatic malignant fibrous histiocytoma: an analysis of prognostic factors. Ann. Thorac. Surg. 80, 1847–1852 (2005).
Blackmon, S. H. et al. Resection of pulmonary and extrapulmonary sarcomatous metastases is associated with long-term survival. Ann. Thorac. Surg. 88, 877–884 (2009).
Assouad, J. et al. Renal cell carcinoma lung metastases surgery: pathologic findings and prognostic factors. Ann. Thorac. Surg. 84, 1114–1120 (2007).
Murthy, S. C. et al. Can we predict long-term survival after pulmonary metastasectomy for renal cell carcinoma? Ann. Thorac. Surg. 79, 996–1003 (2005).
Balch, C. M. et al. Prognostic factors analysis of 17,600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system. J. Clin. Oncol. 19, 3622–3634 (2001).
Clavero, J. M. et al. Gynecologic cancers: factors affecting survival after pulmonary metastasectomy. Ann. Thorac. Surg. 81, 2004–2007 (2006).
Shiono, S. et al. Pulmonary metastasectomy for pulmonary metastases of head and neck squamous cell carcinomas. Ann. Thorac. Surg. 88, 856–860 (2009).
Winter, H. et al. Does surgical resection of pulmonary metastases of head and neck cancer improve survival? Ann. Surg. Oncol. 15, 2915–2926 (2008).
Virgo, K. S., Naunheim, K. S. & Johnson, F. E. Preoperative workup and postoperative surveillance for patients undergoing pulmonary metastasectomy. Thorac. Surg. Clin. 16, 125–131 (2006).
Mineo, T. C., Ambrogi, V., Mineo, D. & Pompeo, E. Transxiphoid hand-assisted videothoracoscopic surgery. Ann. Thorac. Surg. 83, 1978–1984 (2007).
Lo, S. S. et al. Stereotactic body radiation therapy for early-stage non-small-cell lung cancer. Expert Rev. Anticancer Ther. 8, 87–98 (2008).
Fakiris, A. J. et al. Stereotactic body radiation therapy for early-stage non-small-cell lung carcinoma: four-year results of a prospective phase II study. Int. J. Radiat. Oncol. Biol. Phys. 75, 677–682 (2009).
Ernst-Stecken, A., Lambrecht, U., Mueller, R., Sauer, R. & Grabenbauer, G. Hypofractionated stereotactic radiotherapy for primary and secondary intrapulmonary tumors: first results of a phase I/II study. Strahlenther. Onkol. 182, 696–702 (2006).
Forquer, J. A. et al. Brachial plexopathy from stereotactic body radiotherapy in early-stage NSCLC: dose-limiting toxicity in apical tumor sites. Radiother. Oncol. 93, 408–413 (2009).
Timmerman, R. et al. Excessive toxicity when treating central tumors in a phase II study of stereotactic body radiation therapy for medically inoperable early-stage lung cancer. J. Clin. Oncol. 24, 4833–4839 (2006).
Norihisa, Y. et al. Stereotactic body radiotherapy for oligometastatic lung tumors. Int. J. Radiat. Oncol. Biol. Phys. 72, 398–403 (2008).
Jemal, A. et al. Cancer statistics, 2009. CA Cancer J. Clin. 59, 225–249 (2009).
Donadon, M., Ribero, D., Morris-Stiff, G., Abdalla,E. K. & Vauthey, J. N. New paradigm in the management of liver-only metastases from colorectal cancer. Gastrointest. Cancer Res. 1, 20–27 (2007).
Abdalla, E. K. et al. Improving resectability of hepatic colorectal metastases: expert consensus statement. Ann. Surg. Oncol. 13, 1271–1280 (2006).
Hughes, K. S. et al. Resection of the liver for colorectal carcinoma metastases: a multi-institutional study of patterns of recurrence. Surgery 100, 278–284 (1986).
Scheele, J., Stangl, R. & Altendorf-Hofmann, A. Hepatic metastases from colorectal carcinoma: impact of surgical resection on the natural history. Br. J. Surg. 77, 1241–1246 (1990).
Charnsangavej, C. et al. Selection of patients for resection of hepatic colorectal metastases: expert consensus statement. Ann. Surg. Oncol. 13, 1261–1268 (2006).
Fong, Y., Gonen, M., Rubin, D., Radzyner, M. & Brennan, M. F. Long-term survival is superior after resection for cancer in high-volume centers. Ann. Surg. 242, 540–544 (2005).
Mainenti, P. P. et al. Detection of colo-rectal liver metastases: prospective comparison of contrast enhanced US, multidetector, CT, PET/CT, and 1.5 Tesla MR with extracellular and reticulo-endothelial cell specific contrast agents. Abdom. Imaging 35, 511–521 (2010).
Rappeport, E. D. et al. Contrast-enhanced FDG-PET/CT vs. SPIO-enhanced MRI vs. FDG-PET vs. CT in patients with liver metastases from colorectal cancer: a prospective study with intraoperative confirmation. Acta Radiol. 48, 369–378 (2007).
Carpizo, D. R. et al. Liver resection for metastatic colorectal cancer in patients with concurrent extrahepatic disease: results in 127 patients treated at a single center. Ann. Surg. Oncol. 16, 2138–2146 (2009).
Pawlik, T. M. et al. Trends in nontherapeutic laparotomy rates in patients undergoing surgical therapy for hepatic colorectal metastases. Ann. Surg. Oncol. 16, 371–378 (2009).
Parks, R. et al. Adjuvant chemotherapy improves survival after resection of hepatic colorectal metastases: analysis of data from two continents. J. Am. Coll. Surg. 204, 753–761 (2007).
Nordlinger, B. et al. Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial. Lancet 371, 1007–1016 (2008).
Reddy, S. K. et al. Timing of multimodality therapy for resectable synchronous colorectal liver metastases: a retrospective multi-institutional analysis. Ann. Surg. Oncol. 16, 1809–1819 (2009).
Adam, R. et al. Tumor progression while on chemotherapy: a contraindication to liver resection for multiple colorectal metastases? Ann. Surg. 240, 1052–1061 (2004).
Blazer, D. G. 3rd et al. Pathologic response to preoperative chemotherapy: a new outcome end point after resection of hepatic colorectal metastases. J. Clin. Oncol. 26, 5344–5351 (2008).
Gallagher, D. J. et al. Response to neoadjuvant chemotherapy does not predict overall survival for patients with synchronous colorectal hepatic metastases. Ann. Surg. Oncol. 16, 1844–1851 (2009).
Scoggins, C. R. et al. Preoperative chemotherapy does not increase morbidity or mortality of hepatic resection for colorectal cancer metastases. Ann. Surg. Oncol. 16, 35–41 (2009).
Adam, R. et al. Patients with initially unresectable colorectal liver metastases: is there a possibility of cure? J. Clin. Oncol. 27, 1829–1835 (2009).
Bismuth, H. et al. Resection of nonresectable liver metastases from colorectal cancer after neoadjuvant chemotherapy. Ann. Surg. 224, 509–520 (1996).
Sarpel, U. et al. Does anatomic versus nonanatomic resection affect recurrence and survival in patients undergoing surgery for colorectal liver metastasis? Ann. Surg. Oncol. 16, 379–384 (2009).
Reddy, S. K. et al. Simultaneous resections of colorectal cancer and synchronous liver metastases: a multi-institutional analysis. Ann. Surg. Oncol. 14, 3481–3491 (2007).
Martin, R. et al. Simultaneous liver and colorectal resections are safe for synchronous colorectal liver metastasis. J. Am. Coll. Surg. 197, 233–241 (2003).
Schwarz, R. E. Visceral organ resections combined with synchronous major hepatectomy: examples of safety and feasibility. HPB 5, 27–32 (2003).
Wicherts, D. A. et al. Long-term results of two-stage hepatectomy for irresectable colorectal cancer liver metastases. Ann. Surg. 248, 994–1005 (2008).
Chun, Y. S. et al. Systemic chemotherapy and two-stage hepatectomy for extensive bilateral colorectal liver metastases: perioperative safety and survival. J. Gastrointest. Surg. 11, 1498–1504 (2007).
Ribero, D. et al. Portal vein embolization before major hepatectomy and its effects on regeneration, resectability and outcome. Br. J. Surg. 94, 1386–1394 (2007).
Covey, A. M. et al. Combined portal vein embolization and neoadjuvant chemotherapy as a treatment strategy for resectable hepatic colorectal metastases. Ann. Surg. 247, 451–455 (2008).
Poon, R. T. et al. Improving perioperative outcome expands the role of hepatectomy in management of benign and malignant hepatobiliary diseases: analysis of 1222 consecutive patients from a prospective database. Ann. Surg. 240, 698–708 (2004).
Gold, J. S. et al. Increased use of parenchymal-sparing surgery for bilateral liver metastases from colorectal cancer is associated with improved mortality without change in oncologic outcome: trends in treatment over time in 440 patients. Ann. Surg. 247, 109–117 (2008).
Jarnagin, W. R. et al. Improvement in perioperative outcome after hepatic resection: analysis of 1,803 consecutive cases over the past decade. Ann. Surg. 236, 397–406 (2002).
Rees, M., Tekkis, P. P., Welsh, F. K., O'Rourke, T. & John, T. G. Evaluation of long-term survival after hepatic resection for metastatic colorectal cancer: a multifactorial model of 929 patients. Ann. Surg. 247, 125–135 (2008).
de Haas, R. J. et al. R1 resection by necessity for colorectal liver metastases: is it still a contraindication to surgery? Ann. Surg. 248, 626–637 (2008).
de Jong, M. C. et al. Rates and patterns of recurrence following curative intent surgery for colorectal liver metastasis: an international multi-institutional analysis of 1669 patients. Ann. Surg. 250, 440–448 (2009).
Scheele, J., Stang, R., Altendorf-Hofmann, A. & Paul, M. Resection of colorectal liver metastases. World J. Surg. 19, 59–71 (1995).
Tomlinson, J. S. et al. Actual 10-year survival after resection of colorectal liver metastases defines cure. J. Clin. Oncol. 25, 4575–4580 (2007).
Brachet, D. et al. Prognostic factors of survival in repeat liver resection for recurrent colorectal metastases: review of sixty-two cases treated at a single institution. Dis. Colon Rectum 52, 475–483 (2009).
Ishiguro, S. et al. Second hepatectomy for recurrent colorectal liver metastasis: analysis of preoperative prognostic factors. Ann. Surg. Oncol. 13, 1579–1587 (2006).
Sa Cunha, A. et al. A second liver resection due to recurrent colorectal liver metastases. Arch. Surg. 142, 1144–1149 (2007).
Shaw, I. M., Rees, M., Welsh, F. K., Bygrave, S. & John, T. G. Repeat hepatic resection for recurrent colorectal liver metastases is associated with favourable long-term survival. Br. J. Surg. 93, 457–464 (2006).
Thelen, A. et al. Repeat liver resection for recurrent liver metastases from colorectal cancer. Eur. J. Surg. Oncol. 33, 324–328 (2007).
Kattan, M. W. et al. A nomogram for predicting disease-specific survival after hepatic resection for metastatic colorectal cancer. Ann. Surg. 247, 282–287 (2008).
Adam, R. et al. Hepatic resection for noncolorectal nonendocrine liver metastases: analysis of 1,452 patients and development of a prognostic model. Ann. Surg. 244, 524–535 (2006).
Ercolani, G. et al. The role of liver resections for noncolorectal, nonneuroendocrine metastases: experience with 142 observed cases. Ann. Surg. Oncol. 12, 459–466 (2005).
Reddy, S. K. et al. Resection of noncolorectal nonneuroendocrine liver metastases: a comparative analysis. J. Am. Coll. Surg. 204, 372–382 (2007).
Weitz, J. et al. Partial hepatectomy for metastases from noncolorectal, nonneuroendocrine carcinoma. Ann. Surg. 241, 269–276 (2005).
Yedibela, S. et al. Changes in indication and results after resection of hepatic metastases from noncolorectal primary tumors: a single-institutional review. Ann. Surg. Oncol. 12, 778–785 (2005).
Fortner, J. G. & Fong, Y. Twenty-five-year follow-up for liver resection: the personal series of Dr. Joseph G. Fortner. Ann. Surg. 250, 908–913 (2009).
Touzios, J. G. et al. Neuroendocrine hepatic metastases: does aggressive management improve survival? Ann. Surg. 241, 776–783 (2005).
Adam, R. et al. Is liver resection justified for patients with hepatic metastases from breast cancer? Ann. Surg. 244, 897–907 (2006).
Hoffmann, K. et al. Liver resection for multimodal treatment of breast cancer metastases: identification of prognostic factors. Ann. Surg. Oncol. 17, 1546–1554 (2010).
Thelen, A. et al. Liver resection for metastases from breast cancer. J. Surg. Oncol. 97, 25–29 (2008).
Vlastos, G. et al. Long-term survival after an aggressive surgical approach in patients with breast cancer hepatic metastases. Ann. Surg. Oncol. 11, 869–874 (2004).
Rehders, A. et al. Hepatic metastasectomy for soft-tissue sarcomas: is it justified? World J. Surg. 33, 111–117 (2009).
Okano, K. et al. Hepatic resection for metastatic tumors from gastric cancer. Ann. Surg. 235, 86–91 (2002).
Hsueh, E. C. et al. Prolonged survival after complete resection of metastases from intraocular melanoma. Cancer 100, 122–129 (2004).
Mariani, P. et al. Surgical management of liver metastases from uveal melanoma: 16 years' experience at the Institut Curie. Eur. J. Surg. Oncol. 35, 1192–1197 (2009).
Pawlik, T. M. et al. Hepatic resection for metastatic melanoma: distinct patterns of recurrence and prognosis for ocular versus cutaneous disease. Ann. Surg. Oncol. 13, 712–720 (2006).
DeMatteo, R. P. et al. Results of tyrosine kinase inhibitor therapy followed by surgical resection for metastatic gastrointestinal stromal tumor. Ann. Surg. 245, 347–352 (2007).
Ben-Josef, E. et al. Phase II trial of high-dose conformal radiation therapy with concurrent hepatic artery floxuridine for unresectable intrahepatic malignancies. J. Clin. Oncol. 23, 8739–8747 (2005).
Dawson, L. A. et al. Escalated focal liver radiation and concurrent hepatic artery fluorodeoxyuridine for unresectable intrahepatic malignancies. J. Clin. Oncol. 18, 2210–2218 (2000).
Krishnan, S. et al. Conformal radiotherapy of the dominant liver metastasis: a viable strategy for treatment of unresectable chemotherapy refractory colorectal cancer liver metastases. Am. J. Clin. Oncol. 29, 562–567 (2006).
Mohiuddin, M., Chen, E. & Ahmad, N. Combined liver radiation and chemotherapy for palliation of hepatic metastases from colorectal cancer. J. Clin. Oncol. 14, 722–728 (1996).
Kavanagh, B. D. et al. Interim analysis of a prospective phase I/II trial of SBRT for liver metastases. Acta Oncol. 45, 848–855 (2006).
Schefter, T. E. et al. A phase I trial of stereotactic body radiation therapy (SBRT) for liver metastases. Int. J. Radiat. Oncol. Biol. Phys. 62, 1371–1378 (2005).
Blomgren, H., Lax, I., Näslund, I. & Svanström, R. Stereotactic high dose fraction radiation therapy of extracranial tumors using an accelerator. Clinical experience of the first thirty-one patients. Acta Oncol. 34, 861–870 (1995).
van der Pool, A. E. et al. Stereotactic body radiation therapy for colorectal liver metastases. Br. J. Surg. 97, 377–382 (2010).
Méndez Romero, A. et al. Stereotactic body radiation therapy for primary and metastatic liver tumors: a single institution phase I–II study. Acta Oncol. 45, 831–837 (2006).
Hoyer, M. et al. Phase II study on stereotactic body radiotherapy of colorectal metastases. Acta Oncol. 45, 823–830 (2006).
Curley, S. A. et al. Early and late complications after radiofrequency ablation of malignant liver tumors in 608 patients. Ann. Surg. 239, 450–458 (2004).
Gillams, A. R. The use of radiofrequency in cancer. Br. J. Cancer 92, 1825–1829 (2005).
Berber, E., Tsinberg, M., Tellioglu, G., Simpfendorfer, C. H. & Siperstein, A. E. Resection versus laparoscopic radiofrequency thermal ablation of solitary colorectal liver metastasis. J. Gastrointest. Surg. 12, 1967–1972 (2008).
Abdalla, E. K. et al. Recurrence and outcomes following hepatic resection, radiofrequency ablation, and combined resection/ablation for colorectal liver metastases. Ann. Surg. 239, 818–825 (2004).
Bleicher, R. J. et al. Radiofrequency ablation in 447 complex unresectable liver tumors: lessons learned. Ann. Surg. Oncol. 10, 52–58 (2003).
Elias, D. et al. Local recurrences after intraoperative radiofrequency ablation of liver metastases: a comparative study with anatomic and wedge resections. Ann. Surg. Oncol. 11, 500–505 (2004).
Lee, W. S. et al. Clinical outcomes of hepatic resection and radiofrequency ablation in patients with solitary colorectal liver metastasis. J. Clin. Gastroenterol. 42, 945–949 (2008).
Siperstein, A. E., Berber, E., Ballem, N. & Parikh, R. T. Survival after radiofrequency ablation of colorectal liver metastases: 10-year experience. Ann. Surg. 246, 559–565 (2007).
Solbiati, L. et al. Percutaneous radio-frequency ablation of hepatic metastases from colorectal cancer: long-term results in 117 patients. Radiology 221, 159–166 (2001).
Gillams, A. R. & Lees, W. R. Radio-frequency ablation of colorectal liver metastases in 167 patients. Eur. Radiol. 14, 2261–2267 (2004).
Reuter, N. P., Woodall, C. E., Scoggins, C. R., McMasters, K. M. & Martin, R. C. Radiofrequency ablation vs. resection for hepatic colorectal metastasis: therapeutically equivalent? J. Gastrointest. Surg. 13, 486–491 (2009).
Gillams, A. R. & Lees, W. R. Five-year survival in 309 patients with colorectal liver metastases treated with radiofrequency ablation. Eur. Radiol. 19, 1206–1213 (2009).
Hildebrand, P. et al. Radiofrequency-ablation of unresectable primary and secondary liver tumors: results in 88 patients. Langenbecks Arch. Surg. 391, 118–123 (2006).
Iannitti, D. A., Dupuy, D. E., Mayo-Smith, W. W. & Murphy, B. Hepatic radiofrequency ablation. Arch. Surg. 137, 422–426 (2002).
Machi, J. et al. Long-term outcome of radiofrequency ablation for unresectable liver metastases from colorectal cancer: evaluation of prognostic factors and effectiveness in first- and second-line management. Cancer J. 12, 318–326 (2006).
Guckenberger, M. et al. Dose-response relationship for image-guided stereotactic body radiotherapy of pulmonary tumors: relevance of 4D dose calculation. Int. J. Radiat. Oncol. Biol. Phys. 74, 47–54 (2009).
Rosen, C. B. et al. Perioperative blood transfusion and determinants of survival after liver resection for metastatic colorectal carcinoma. Ann. Surg. 216, 493–504 (1992).
Jamison, R. L. et al. Hepatic resection for metastatic colorectal cancer results in cure for some patients. Arch. Surg. 132, 505–510 (1997).
Minagawa, M. et al. Extension of the frontiers of surgical indications in the treatment of liver metastases from colorectal cancer: long-term results. Ann. Surg. 231, 487–499 (2000).
Wei, A. C. et al. Survival after hepatic resection for colorectal metastases: a 10-year experience. Ann. Surg. Oncol. 13, 668–676 (2006).
Shah, S. A. et al. Survival after liver resection for metastatic colorectal carcinoma in a large population. J. Am. Coll. Surg. 205, 676–683 (2007).
Ambrosino, G. et al. Image-guided robotic stereotactic radiosurgery for unresectable liver metastases: preliminary results. Anticancer Res. 29, 3381–3384 (2009).
Author information
Authors and Affiliations
Contributions
R. D. Timmerman and T. E. Olencki contributed to researching the data for the article and editing the manuscript before submission. B. S. Teh, N. A. Mayr, J. J. Lu and J. C. Grecula contributed to researching the data for the article, discussions of the content and editing the manuscript before submission. S. S. Lo, S. D. Moffatt-Bruce, L. A. Dawson and R. E. Schwarz contributed to researching the data for the article, discussions of the content, writing the article and editing the manuscript before submission.
Corresponding author
Ethics declarations
Competing interests
L. A. Dawson declares associations with the following company and organization: Bayer and the Canadian Institutes of Health and Research. R. D. Timmerman declares associations with the following companies and organization: Varian Medical Systems, Accuray and the US Department of Defense. The other authors declare no competing interests.
Rights and permissions
About this article
Cite this article
Lo, S., Moffatt-Bruce, S., Dawson, L. et al. The role of local therapy in the management of lung and liver oligometastases. Nat Rev Clin Oncol 8, 405–416 (2011). https://doi.org/10.1038/nrclinonc.2011.75
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrclinonc.2011.75
This article is cited by
-
Metastasis-directed therapy for oligometastasis and beyond
British Journal of Cancer (2021)
-
Recursive partitioning analysis of patients with oligometastatic non-small cell lung cancer: a retrospective study
BMC Cancer (2019)
-
Eradication of unresectable liver metastasis through induction of tumour specific energy depletion
Nature Communications (2019)
-
Outcomes of concurrent chemoradiotherapy versus chemotherapy alone for stage IV esophageal squamous cell carcinoma: a retrospective controlled study
Radiation Oncology (2018)
-
The emerging role of stereotactic radiotherapy in gastrointestinal malignancies: a review of the literature and analysis from the Irish perspective
Irish Journal of Medical Science (1971 -) (2018)